Pulmonary-Allergy Drugs Advisory Committee Meeting Tiotropium Inhalation Spray (Spiriva Respimat) NDA[removed]FDA Introductory Remarks - Respimat - Document - PDFSEARCH.IO

First Page	Meta Content
	Pulmonary-Allergy Drugs Advisory Committee Meeting Tiotropium Inhalation Spray (Spiriva Respimat) NDA[removed]FDA Introductory Remarks Add to Reading List Open Document File Size: 976,55 KB Share Result on Facebook MedicalCondition chronic obstructive pulmonary disease / Potential stroke / myocardial infarction / stroke / bronchospasm / COPD / / Organization FDA / Pulmonary-Allergy Drugs Advisory Committee / Pulmonary / Allergy / and Rheumatology Products Center for Drug Evaluation / Food and Drug Administration / / Person Ann Intern Med / / Position Deputy Director for Safety Division / / Product Spiriva / / Technology Pharmacokinetics / / SocialTag Epoxides Pfizer Tiotropium bromide Medicine Health Chronic obstructive pulmonary disease Respimat Acute exacerbation of chronic obstructive pulmonary disease Chemistry Muscarinic antagonists

Pulmonary-Allergy Drugs Advisory Committee Meeting Tiotropium Inhalation Spray (Spiriva Respimat) NDA[removed]FDA Introductory RemarksAdd to Reading List